| Similar Articles |
|---|
 |
The Motley Fool
January 5, 2004
Alyce Lomax |
Side Effects at Lilly? Growing profits, with earnings pains.   |
Insurance & Technology
August 31, 2009
Nathan Conz |
Conseco To Consolidate Insurance Subsidiaries Conseco has announced a plan to consolidate three insurance companies within its Conseco Insurance Group segment. |
The Motley Fool
June 14, 2004
Brian Gorman |
Elan Teams Up With Lilly The companies' manufacturing agreement may be more of a positive sign for Eli Lilly than it is for Elan. |
The Motley Fool
April 19, 2004
Alyce Lomax |
Eli Lilly's Drug Dependency Competitive concerns make Cymbalta and new drugs more important than ever. |
The Motley Fool
January 28, 2011
Brian Orelli |
Avoid This Falling Knife for Now 2011 could be just the start of a long slide for Lilly. And 2012 will see difficult year-over-year comparison. |
CFO
June 1, 2003
Alix Nyberg |
Second Acts After bankruptcy, companies often teeter between encore and final curtain call. |
The Motley Fool
June 2, 2009
Dan Caplinger |
3 Bankruptcies That Actually Helped Investors Some bankrupt companies made good investments. Take a look at: Conseco... Delta Airlines... UAL Corp. ... |
The Motley Fool
April 17, 2007
Ryan Fuhrmann |
Clean Bill of Health at Eli Lilly Lilly recorded another solid quarter, but its valuation is a little rich. |
The Motley Fool
December 12, 2008
Brian Orelli |
A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors. |
The Motley Fool
April 22, 2008
Brian Lawler |
Lilly in Full Financial Bloom Pharmaceutical Eli Lilly boosts revenue in the first quarter, but its drug-pipeline progress falls short of spectacular. |
The Motley Fool
June 10, 2005
Stephen D. Simpson |
The High Cost of Diabetes Settling claims related to Zyprexa was probably the best of a bad set of choices for Eli Lilly. Investors need to remember to incorporate this as a risk factor for all drug companies. |
The Motley Fool
November 29, 2011
Dan Caplinger |
Has Eli Lilly Become the Perfect Stock? The reason Lilly offers such an attractive yield and cheap valuation is that investors aren't sure it can keep up its past success. |
The Motley Fool
July 21, 2005
Stephen D. Simpson |
Tiger Lilly or Wilting Daisy? For now, Lilly seems to me to be a middle-of-the-road type of pharmaceutical stock. There are plenty of worse ideas out there, but there are better ideas, as well. |
The Motley Fool
March 24, 2005
Brian Gorman |
Eli Lilly Turns to Japan The company's move to focus more resources on Japan makes good sense. |
